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Case presentation
A 46-year-old man was admitted to the hospital for evaluation of
hypertension. When previously hospitalized at age 40 for a fractured
cervical spine, he was hypertensive. The patient had had no prior
measurements of blood pressure. He had received no further medical
attention until 3 weeks prior to admission, when he was seen by a family
physician for a rash on his legs. Although he was otherwise asymptom-
atic, he was found to be severely hypertensive. Therapy with thiazide
diuretics and a beta blocker did not restore his blood pressure to
normal, and hospitalization was advised. The patient denied hematuria,
flank pain, urinary tract infections, edema, arthralgias, and urolithiasis.
The history disclosed nocturia for one year and an allergy to penicillin;
he had had a posttraumatic splenectomy in his youth. His father, who
lived in the same community, had hypertension and an unspecified
renal disease. The patient drank 3 to 5 beers daily.
Physical examination revealed a blood pressure of 230/115 mm Hg
without postural changes. Pulse was 60 and regular. He had severe
pyorrhea but no other oral lesions. Fundi revealed grade-LI hyperten-
sive retinopathy. No abdominal or cervical bruits were noted. Cardiac
examination revealed a prominent S4 but was otherwise unremarkable.
The abdomen was protuberant, and the liver edge was firm and palpable
2 cm below the right costal margin. Femoral and dorsalis pedis pulses
were symmetrical and slightly decreased. The prostate was normal.
Chest x-ray revealed left ventricular prominence but no frank cardio-
megaly. An electrocardiogram showed left ventricular hypertrophy by
voltage criteria. Radiographs of long bones disclosed no abnormalities.
Renal ultrasound revealed 10 cm kidneys bilaterally with compact
collecting system. Two creatinine clearances were 23 to 28 mi/min/ I .73
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m2. The 24-hr urine protein excretion was 490 mg. Urinalysis revealed
no pyuria, hematuria, or cylindruria. Hemoglobin was 14.2 g/dl; hemat-
ocrit was 41%, The white blood cell count was 8900/mm3 with a normal
differential. The platelet count was 281,000/mm3, and the erythrocyte
sedimentation rate was 22 mm/hr. Electrolyte values were: sodium, 141
mEq/liter; potassium, 5.1 mEq/liter; chloride, Ill mEq/liter; and bicar-
bonate, 18 mEq/liter. Calcium was 9.0 mg/dl; phosphate, 5.3 mg/dl; uric
acid, 10.8 mg/dl; and fasting blood sugar, 82 mg/dI. The BUN was 64
mgldl and the serum creatinine was 3.9 mg/dl. Coagulation and liver
function studies were normal. An antinuclear antibody test was nega-
tive. Hepatitis B surface antigen and core antibody were not detected.
The third and fourth components of complement were normal. Light
chains were not detected in the urine.
A renal biopsy (Fig. 1) revealed severe tubulointerstitial disease and
nephrosclerosis with sclerosis of at least 70% of the glomeruli. Tubular
basement membranes were multilaminated with crystalline calcium
deposits within the multilaminations. There was no evidence of immu-
noglobulin deposition in glomeruli or tubular basement membranes.
Amyloid stains were negative. Electron microscopy revealed no
glomerular electron-dense deposits.
Routine review of the patient's occupational history revealed 25
years of employment in various capacities for a lead mining company.
He had transferred to his present job of a crane operator after a blood
lead level 16 years previously allegedly was 180 gIdl. Whole blood lead
concentration during this hospitalization was 59 .tgJml (normal, <30 g/
dl). Erythrocyte protoporphyrin was 180 g/dl (normal, 250 sg/d1).
Calcium EDTA lead mobilization test (I g given in 2 doses separated by
12 hours) revealed 3266 g in the first 24 hours (normal, <800 W24 hr).
The patient's blood pressure was controlled by a combination of
hydralazine, nadolol, and furosemide. He received EDTA chelation
treatments at 2-week intervals for 6 months. After one month, another
lead mobilization test showed 950 sg of lead in 24 hours. After 6
months, excretion of lead was 930 g in 24 hours, At the most recent
follow-up, 3 years after diagnosis, his BUN was 56 mg/dl, creatinine 3.6
mg/dl, and creatinine clearance 23 mlIminIl .73 m2.
Discussion
DR. WILLIAM M. BENNETT (Professor of Medicine and
Pharmacology, Division of Nephrology, Oregon Health Sci-
ences University, Portland, Oregon): The fascinating history of
lead poisoning parallels that of civilization. Extraction of silver
ore in Roman times produced large amounts of lead as a by-
product of the mining process. Lead ingestion was probably
widespread among the Romans, because pipes and utensils
containing lead pigments were used to transport and cook their
food. Indeed, lead poisoning is thought by some to have
contributed to the decline of the Roman Empire [1]. The first
known clinical description of lead poisoning was made by a
Greek poet, Nikander of Colophon, in 200 B.C. Saturnine gout,
a manifestation of lead poisoning, was common in Roman
times. An increasing problem of gout among women was
mentioned by Seneca after rules were relaxed prohibiting
women from drinking wines presumably laden with lead. Two
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Fig. 1. Renal biopsy shows severe nonspecific chronic tubulointerstitial disease. Most tubules are collapsed and atrophic; the interstitium is
expanded by dense fibrosis and lymphocytic infiltrates. Severe arterio- and arteriolosclerosis, not shown here, were evident in many areas of the
biopsy (Jones methenamine silver; X240.)
thousand years later, Emmerson identified a higher percentage
of females among gouty patients with lead poisoning than is
observed in primary gout, in which males overwhelmingly
predominate [21. In 1862, Lancereaux identified lead-associated
chronic tubulointerstitial nephritis and even emphasized its
distinction from Bright's disease because of the absence of
proteinuria [31.
Hypertension and renal failure due to lead were well recog-
nized by clinicians by the late 19th century [1, 4]. Despite
substantial evidence implicating lead as a causal factor in renal
disease, lead and other environmental toxins have been ignored
by physicians in the past 50 years, perhaps because identifying
particular causes of end-stage renal disease usually had little or
no therapeutic value [4].
The patient under discussion, whose history of untreated
hypertension dates back at least 6 years, first seemed to be a
straightforward example of hypertensive nephrosclerosis, and
the findings on his renal biopsy are consistent with that
diagnosis.
Toxic nephropathy is reported to cause only about 1% of all
cases of end-stage renal disease requiring dialysis or transplan-
tation [5]. One wonders how many patients are characterized in
official registries as having chronic glomerulonephritis, chronic
tubulointerstitial nephritis, or hypertensive nephrosclerosis as
their primary diagnosis who, in fact, have nephrotoxic environ-
mental exposure as the cause of chronic renal damage. In the
vast majority of patients given these descriptive diagnoses, no
definite episode of acute glomerulonephritis or pyelonephritis is
identified. I should like to make the case that lead poisoning is
the cause of the renal failure in the patient we are discussing
today, and possibly in many others.
Physiology
Lead is concentrated in kidneys, bone, teeth, and hair within
an hour after absorption from the gut. The rate of renal
excretion depends on the amount and duration of exposure [6].
Acute administration of lead results in excretion via glomerular
filtration and tubular secretion [7]. Lead enters into renal
tubular cells across the luminal and basolateral membranes. In
rat renal cortical slices, lead enters the cell as a free ion,
probably by an active transport process [7]. Effiux of lead from
cortical slices preloaded in vitro can be increased by metabolic
inhibitors [7]. Lead accumulation is markedly reduced by tin
but not by other metals; it is possible that lead and tin compete
for a common carrier [8]. In dogs, metabolic acidosis reduces
fractional lead excretion, whereas metabolic alkalosis enhances
net tubular secretion by increasing entry into the cell across the
peritubular membrane [9].
Renal tubular function was examined by Hong et a! in 6 lead-
exposed workers with normal levels of BUN and serum creati-
nine and only trivial decreases in inulin clearance. Urinary /3-2
microglobulin, PAH secretory capacity, bicarbonate reabsorp-
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tive capacity, and effective renal plasma flow all were normal,
but tubular reabsorptive capacity for glucose was markedly
decreased in all 6 patients [101. Data showing a decreased
capacity of rat renal cortical slices to synthesize glucose from
pyruvate are consistent with these findings [11]. Presumably,
lead-induced impairment in mitochondrial oxidative phospho-
rylation [12] reduces tubular glucose transport capacity.
Because of the strong association between gout and chronic
lead nephropathy, Emmerson and coworkers studied the renal
handling of uric acid in patients with saturnine gout. By using
pyrazinamide to inhibit renal tubular secretion of urate, they
demonstrated an enhancement of fractional uric acid reabsorp-
tion relative to the degree of renal failure [131.
In some instances, reversible suppression of plasma renin
activity with hyporeninemic hypoaldosteronism has been re-
ported with chronic lead poisoning [14, 15]. Although acute lead
exposure increases urinary sodium excretion and plasma renin
activity in rats and dogs [16], prolonged exposure produces a
blunted renin response to sodium deprivation perhaps analo-
gous to renin suppression observed with similar stimuli in the
clinical situation [17].
Occupational lead exposure also can alter the elimination
half-life of compounds that depend on hepatic metabolism for
excretion, such as antipyrine and phenylbutazone. This type of
interference with hepatic drug metabolism could exacerbate
lead's nephrotoxic effects [18]. Experimental data also have
emphasized the complex toxic interactions of lead with other
trace elements such as cadmium, zinc, copper, selenium, and
arsenic [19, 201. For example, acute lead administration in-
creases urinary losses of zinc in dogs [21].
Chronic lead ingestion in mice and hamsters has been report-
ed to induce renal neoplasms [22]. This may be a result of a
complex interaction between this toxin and intracellular regula-
tory processes. The finding that lead can induce immunologic
abnormalities in mice raises the possibility that the kidney also
could be injured by immune mechanisms after chronic low-level
exposure [23].
Diagnosis of lead nephropathy
Diagnosing lead nephropathy is difficult because symptoms
of lead intoxication are variable and nonspecific. Of 31 occupa-
tionally exposed patients with documented increased body
burdens of lead and with abnormalities of at least one major
organ system, 29% were totally asymptomatic and an additional
26% complained only of fatigue [24].
A diagnosis of lead nephropathy can only be made if the
clinician is alert to this possibility and takes a history that will
elicit an occupational or environmental lead exposure in all
patients with renal disease. Because a history of exposure only
represents circumstantial evidence of causality, evidence of an
increased body lead burden must be convincing. In the past,
blood lead levels have been used as the "gold standard" for
diagnosing intoxication. Unfortunately, an elevated blood lead
level correlates best with recent exposure, and a normal value
does not exclude a remote exposure with an increased body
burden. The patient under discussion here had had an extreme-
ly high blood lead concentration in the past and it was still
abnormal years later. This finding almost certainly signifies
both remote and continuing exposure.
The most accurate test in patients at risk is an EDTA lead
mobilization test, which can document an excessive body lead
burden [4]. Batumen et al used the lead mobilization test in 48
patients who were considered to have essential hypertension
[251. The test involves two intramuscular injections of 0.5 g of
EDTA 12 hours apart. EDTA is able to chelate lead sequestered
in body storage sites and mobilize it for renal excretion in the
form of a lead-EDTA chelate. Individuals who have not been
exposed to unusual amounts of lead usually excrete in the urine
less than 650 jig of lead in 24 hours. In patients with renal
failure, collection periods should be extended to 3 to 6 days. Of
the 21 patients with renal impairment (as evidenced by serum
creatinine greater than 1.5 mgldl) whom Batumen et al studied,
lead excretion was 860 jig per 3 days as compared to 340 jig for
27 hypertensive patients with normal renal function and 440 jig
in subjects with other renal diseases. Medical histories were
unreliable as evidence of exposure.
Determining erythrocyte protoporphyrin levels also has been
used as a diagnostic procedure for determining excess lead
exposure. Protoporphyrin, a metabolic intermediate, accumu-
lates in red cells because lead inhibits ferrochelatase, the
catalyst of iron transfer from ferritin to protoporphyrin. Elevat-
ed values persist for the life of the red blood cell; therefore an
exposure within several months can be detected even when
blood lead concentrations are normal. Unfortunately, normal
values can be observed with remote exposure even when an
excess amount of lead is documented by the chelation (that is,
EDTA) test.
An increase in the lead content of bone was demonstrated in
renal patients with childhood lead exposure but not in other
patients dying of renal failure [26]. Finger bone lead content can
be estimated by the convenient method of x-ray fluorescence.
Approximately 40% of patients with positive EDTA tests had
negative results, however [27]. Likewise, hair analysis can
show accumulation of trace metals [28], but this technique has
not been rigorously evaluated for purposes of diagnosing past
lead exposure.
In 1973 Emmerson outlined criteria for diagnosing chronic
lead nephropathy. Long-standing, progressive, chronic renal
disease and uniformly contracted kidneys in the presence of
excessive lead absorption still remain the most satisfactory
diagnostic criteria. Other known causes of nephropathy must be
excluded. In Emmerson's large experience, more than 50% of
patients with lead nephropathy had gout [31. Men and women
were equally affected, as opposed to primary gout, which
affects males predominantly [29]. Because renal disease often
preceded gout, Emmerson suggested that physicians should
suspect lead nephropathy in patients with renal failure who
develop gout. Other features that differentiated lead-related
gout from primary gout were hypertension, mental impairment
presumably due to lead encephalopathy, and a family history of
renal failure [30].
Clinical renal syndromes of lead intoxication
Hypertension is prominent in workers known to be chronical-
ly exposed to lead [31], so it is possible that lead nephrotoxicity
is a cause of secondary hypertension. Although a study of lead
workers in the l960s failed to find an increased prevalence of
hypertension [32], Beevers et al more recently found that 135
hypertensive patients had higher blood lead concentrations than
did sex- and age-matched normotensive controls [33].
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Massive acute lead exposure can result in hemolytic anemia,
abdominal pain, and usually encephalopathy and peripheral
neuropathy. Proximal renal tubular dysfunction with Fanconi
syndrome can be present [34, 35]. Blood lead concentrations
greater than 70 g/dl are common. Aminoaciduna and phospha-
tuna are correlated with proximal tubular intranuclear inclusion
bodies on renal biopsy [36]. These inclusions contain both lead
and a lead-binding protein [37, 38]. Cells shed into the urine can
contain the same eosinophilic inclusions [36]. Chelation therapy
and withdrawal from the exposure source produce a prompt
therapeutic response.
Chronic lead intoxication can result from continual or inter-
mittent exposure. Although dose-related dysfunction of the
central nervous system, endocrine glands, and hematopoietic
system can occur, symptoms usually are nonspecific, and the
patient's illness frequently is attributed to psychogenic factors.
Renal disease often remains clinically silent until hypertension
or consequences of renal failure supervene—perhaps years
after exposure. This lack of clinical manifestations is undoubt-
edly why the diagnosis is not often considered.
Wedeen, Mallik, and Batumen studied renal function in lead
workers with possible excessive body lead burden [39]. Of 140
individuals examined, 135 were asymptomatic, but 113 excreted
more than 1000 g of lead per day. Detailed renal function
studies were performed in 57 of the 113 (28 refused and 28 had
other diseases, including essential hypertension in 12 and gout
in 4). Of those 57, 36 had normal glomerular filtration rate and
effective renal plasma flow, whereas 21 had abnormal results.
Renal biopsy in 12 patients with abnormal GFRs were normal in
6 and showed light-microscopic evidence of focal tubulointersti-
tial nephropathy in the other 6. However, glomerular and
tubular immunoglobulin deposition was noted in 7 of 8 speci-
mens examined by immunofluorescence. Ultrastructural le-
sions of proximal tubules including mitochondrial swelling with
loss of cristae, lysosomal-like structures with dense bodies, and
loss of brush border were seen in all 10 specimens examined.
The intranuclear inclusions described in children with acute
exposure were absent. There was little correlation between the
presence of documented renal disease and the blood lead
concentration. Even excluding the 6 patients who had other
explanations for a GFR less than 90 mllmin (5 older than 55
years, sustained hypertension in 1), 15 patients or 16% of the
asymptomatic lead workers had definite renal disease associat-
ed with excessive body lead burdens. Finally, Meyer and
colleagues reported increased urinary excretion of the proximal
tubular enzyme N-acetylglucosaminidase in 29 workers ex-
posed to lead at their workplace as compared to unexposed
control workers. Conventional renal function tests were normal
and no correlation was found between blood lead and erythro-
cyte protoporphyrin levels [401. The long-term clinical signifi-
cance of abnormalities in these sensitive markers of renal injury
remains to be established by further studies.
Lead and the environment
Despite the fact that lead is ubiquitous, little information
exists about the potential renal effects of low-level exposure
during urban living from sources such as gasoline exhaust and
industrial waste. However, as I stated earlier, low-level expo-
sure may be important as a factor in human hypertension and
renal disease. Much has been made of the fact that primitive
societies without hypertension have low salt intakes. Possibly
more important, however, is the fact that in urban societies lead
excretion after chelation (as well as blood lead concentrations)
are markedly elevated as compared to those of people in
isolated societies. The lead content of air in remote Nepal is
negligible, and blood concentrations of 103 children and adults
averaged 3.4 g/dl [41]. This level is approximately six- to
eightfold less than the "normal values" of 15 to 25 g/dl
reported from laboratories in the United States. Inhalation is
not the only source of chronic exposure; ingestion is an
important portal of lead entry into the body. Children are at
particular risk, because in addition to environmental sources
they can eat lead from contaminated dusts, soils, or painted
surfaces [42].
As anticipated, lead exposure is far more important in
individuals who live in proximity to industries that process lead,
and of course workers in these industries are at greatest risk
(Table 1). The U.S. government estimates that one million tons
of lead are processed and used annually [43]. Several million
Americans work directly with lead or in facilities that handle
lead. Because most exposure is by the respiratory route, people
in proximity to the dust and fumes containing lead face the
highest risk.
Northern Idaho's Shoshone County, the area in which the
patient we are discussing lives, is known to have lead contami-
nation in the soil and ambient air that correlates with blood lead
concentrations in children. "Acceptable" standards were sug-
gested as 1000 ppm in soil and 2 g Pb/rn3 in air. However,
these values were based on keeping blood levels less than 40 ag/
dl. Whether this standard is a safe one, however, is uncertain
[44]. In 1973, 99% of children aged 1 through 9 living within one
mile of a large lead ore smelter in Kellogg, Idaho had blood
levels greater than 40 tg/dl, and 22% had values greater than 80
,.Wdl [451. The smelter that was the source of overt pollution of
the environment is shown in Figure 2. The lead mine in Kellogg
at its peak produced about 20% of the lead, zinc, and silver
refined in the United States and was the largest employer in the
Coeur d'Alene mining district [46]. Under intense pressure from
environmentalists, substantial progress has been made in con-
trolling pollution as evidenced by declining blood lead levels in
residents of Kellogg [46]. The importance of proximity to lead
exposure is also demonstrated by studies in New Jersey. Blood
lead levels in New Jersey children were correlated with the
distance from a major roadway: 8% of 758 children who lived
less than 100 feet from the roadway had blood lead concentra-
tions greater than 60 gIdl. An additional 49% had levels
between 40 and 59 gIdl [47]. It is apparent that these individ-
uals were exposed to excessive amounts of lead.
If the entire population of the Kellogg area had lived in close
proximity to the lead smelter and thus had been exposed to
excess environmental lead in the early 1970s, one might expect
to see an increased prevalence and incidence of renal failure, if
a causative relationship exists. Failure to demonstrate such a
relationship of course would not necessarily exclude an impor-
tant role for exposure, because the population is rather mobile,
particularly in times of high unemployment. Furthermore, the
duration of time following lead exposure might not have been
long enough to produce a detectable effect on the kidneys.
Nonetheless, data from the Health Care Financing System
(HCFA) analyzed by county show that in January 1979, 7 of the
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Table 1. Sources of lead exposurea
Occupational Environmental
Battery factory workers Battery burning
Brass and bronze workers Ceramics making
Cable makers and splicers Cooking in leaden pots
Foundry workers Using herbal medicines
Gun makers Home-distilling alcoholic beverages
Jewelers Using indoor firing ranges
Lead burners and smelters Retaining lead bullets
Metal workers (grinding, Using lead-containing cosmetics
burning, refining) Soldering
Painters Eating from pottery inadequately fired
Pipe cutters
Pottery workers
Printers
Solderers
Stained glass artisans
Welders
a Adapted from Ref. 24.
(personal Communication). These incidence and prevalence
rates are five- to sixfold higher than all other individual counties
in the five-state HCFA end-stage renal disease network. Inter-
estingly, during the same period, the next highest prevalence
rates were in Kittitas and Okanogan counties in the neighboring
state of Washington (117 and 137 per million). These data could
be germane because workers in these coal and silver mines in
these two central Washington counties also might have been
exposed to lead. Excess mortality from chronic renal disease
was recorded among miners in the state of Washington from
1970 to 1979 [481. Among the Shoshone County population of
19,367 in 1981, 2 new end-stage renal disease patients in 1981
produced an incidence rate of 103 per million. Among the rest of
the 955,500 people in Idaho, there were 47 patients; thus, the
incidence rate of end-stage renal disease was 49 per million.
During 1981 Alaska, Oregon, Washington, and Montana had
incidence rates of 31, 52, 49, and 69 per million, respectively.
Detailed studies of the population in Shoshone County for
evidence of renal disease have been precluded by local political
and economic factors. Others have reported greater-than-ex-
pected numbers of deaths from hypertensive diseases and
nonspecific renal disorders during long-term follow-up of 7000
lead production workers [49].
Relationship of lead exposure to chronic renal failure
Fig. 2. Lead smelter in Kellogg, Idaho; the source of massive environ-
mental lead pollution.
21,646 people were undergoing dialysis in Shoshone County,
which includes Kellogg. The prevalence of 323 per million, in
addition to least 2 new patients who began dialysis during the
year, accounted for a minimum incidence of 90 per million
It has been difficult to prove conclusively that an excess body
burden of lead is linked to chronic renal failure, because the
renal disease is manifested years after acute symptoms. Per-
haps the most convincing evidence comes from Queensland,
Australia. In that tropical climate from 1870 to 1920, houses
were built on eight-foot stumps surrounded by verandas with
railings covered with lead-containing paint. Children exposed to
the flaking paint at play developed chronic renal failure and
contracted kidneys 10 to 40 years later at a rate far exceeding
that in the rest of Australia [50]. Follow-up in 1955 of 400
children hospitalized in Australia between 1915 and 1935 for
acute lead poisoning revealed that 108 of the 165 who had died
had chronic nephritis or hypertension [51]. Of those still alive,
17 had proteinuria and hypertension. Henderson and Inglis used
autopsy material to document increased bone lead in these
patients with contracted kidneys who had died of unknown
causes [52]. Similar renal pathology was reported in lead-
exposed workers around the world [40] and in drinkers of
illicitly distilled whiskey from the southern United States [531.
In the latter individuals, excessive body lead burden was
documented. The incidence of renal failure due to lead nephrop-
athy declined in the Queensland population after legislation to
limit lead-based painting of housing was fully implemented in
the l930s. Because of the long latent period, this decline was
observed only in the 1970s and l980s, however. The finding is
consistent with an important causative role for lead in the
chronic renal failure of these patients.
Baker et al reported combined epidemiologic evaluations of
97 lead smelter workers and 53 workers in a lead chemical
factory. A BUN greater than 20 mg/dl (21 to 44 mgldl) was
present in 28 of the 150 (18.7%). The vast majority of these
individuals had had more than 4 years of exposure to lead.
Detailed evaluations of 19 of the chemical workers (the reasons
for selecting these 19 were not stated) revealed that 6 were
—
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•
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hypertensive, 8 had reduced creatinine clearance, and 8 had
diminished concentrating ability. Blood lead was no different
than in nonazotemic workers, and urinary amino acid screens
were negative [54]. Other sources of lead may contribute to
excess body burdens. Lead-contaminated flour has been sug-
gested as a possible cause of chronic renal disease in Yugosla-
via [55, 56].
In 1963, a study appeared that has been widely quoted as
disproving any serious renal consequences of childhood plum-
bism [57]. Tepper reported followup data from a cohort of 165
individuals who had childhood lead poisoning between 1924 and
1941. Of the 139 people whose health status was known, 10 had
died, one from chronic renal failure at age 23 and 3 others in
childhood from continued lead intoxication. Only 42 of the 139
patients were studied by the authors; of those, one patient had
severe hypertension with normal renal function, 3 had abnormal
creatinine clearances (one with proteinuria), and another 3
abnormal urinary concentrating ability. More than 20 years
later, this study remains open to question. Without an age-
matched control group or at least presentation of the raw data,
the reported abnormalities for a group of people in their 30s and
40s cannot be interpreted. Because the duration and extent of
exposure in these cases was likely much less than in Australia,
the data in Ihe Tepper study still might be consistent with the
concept that childhood exposure can yield renal damage dec-
ades later.
The relationship between lead, hypertension, and gout
In view of the recent epidemiologic association of decreased
calcium intake with hypertension [58, 59] and the well-known
observation that dietary deficiencies of calcium, phosphorus,
and iron promote tissue absorption and retention of lead, a
possible contribution of lead in the pathogenesis of essential
hypertension and nephropathy deserves examination [60—62].
Experimental data from primates given lead orally for 9 months
confirm a calcium-lead nutrient interaction [63]. It is of interest
that 50 to 100 years ago, milk was recommended as a dietary
supplement for lead-exposed workers to minimize absorption
[60]. Likewise, patients with both gout and renal failure have
increased body burdens of lead [64]. Reynolds showed that
gouty patients whose one-day EDTA tests were positive had
creatinine clearances of 85 25 mI/mm, whereas those with
normal results of lead mobilization tests had clearances of 111
28 [65]. This observation is of interest because of the well-
known association of gout with overt lead poisoning and the
relative sparing of the kidney in gouty patients in the absence of
aggravating factors such as hypertension [66]. The relationship
between lead and hypertensive renal failure may be part of a
complex interaction among gout, hypertension, and renal fail-
ure. Assuming that chronic lead poisoning produces a nephrop-
athy characterized by chronic interstitial nephritis and nephro-
sclerosis, it is no wonder that instances of lead nephropathy are
misinterpreted as being related only to severe hypertension or
to gouty nephropathy. The vascular changes are present in all
these entities, and the renal pathologic lesion of so-called gouty
nephropathy is characterized by tubulointerstitial scarring and
nephrosclerosis, findings that are totally nonspecific and that
easily could be confused with lead-induced tubular changes and
secondary nephrosclerosis.
Management
When blood lead or erythrocyte protoporphyrin levels are
elevated, removing the source of lead exposure is self-evident.
When exposure has been chronic, chelation therapy should be
considered. Administration of EDTA disrupts the nuclear inclu-
sion bodies in lead-poisoned rats concomitant with increasing
lead excretion in the urine [67]. However, few studies have
documented EDTA's clinical efficacy. Wedeen et al showed
that 4 of 8 patients given EDTA 3 times a week for 6 to 50
months had increases in GFR of greater than 20% [39]. The
other patients maintained stable function.
Although EDTA has been considered a nephrotoxic drug
[68], Wedeen and colleagues have documented the safety of
diagnostic testing with EDTA in 122 patients including 74
individuals with serum creatinine concentrations greater than
1.6 mg/dl [69]. When large amounts of lead are mobilized
suddenly from tissue stores, acute renal failure can result [70,
71]. This toxic effect is not necessarily due to EDTA itself but
rather to lead dissociating from the chelate, because EDTA can
be administered at a later date without untoward renal effects
[70]. British anti-Lewisite (BAL) and D-penicillamine seem to
have no advantage over EDTA in efficacy and are at least
equally toxic.
In patients with renal failure and acute lead encephalopathy,
dialysis may be sufficient and little or no chelation may be
required [72, 73]. In children with acute poisoning, an 8-hour
lead excretion of 200 .tg is considered an indication for chela-
tion therapy [74]. Guidelines for EDTA chelation therapy in
chronic lead poisoning are less clear, because the reservoir of
lead in bone is large and the amount accessible for chelation is
small, making prolonged therapy necessary [75].
A new agent, 2—3 dimercaptosuccinic acid, is remarkably
effective in increasing renal lead excretion when given orally to
rats [76, 77]. Clinical trials have shown a decrease in blood lead
from 97 to 43 tg/d1 with only 6 days of treatment with this drug
in 5 lead-poisoned workers [77]. The drug did not enhance
calcium, zinc, magnesium, or iron excretion, although urinary
copper excretion was significantly increased. Dimercaptopro-
pane sulfonate is another orally administered, water-soluble
chelator that may remove lead specifically from the kidney [78,
79]. Clinical trials are eagerly awaited.
Conclusions
What are the lessons from this seemingly straightforward
case of chronic tubulointerstitial nephropathy with nephroscler-
osis? The correct diagnosis, namely lead nephropathy, was
made only by taking a full history instead of being satisfied with
the descriptive pathologic diagnosis. In view of the paucity of
known primary causes for most patients who progress to end-
stage renal disease, we must always search for potentially
reversible causes of disease. Certainly in patients with pre-
sumed primary hypertension with or without gout, lead
nephropathy should be considered and a careful history of
exposure must be taken. Further evidence for the diagnosis can
be obtained with the EDTA chelation test.
The role of low-level exposure to environmental nephrotox-
ins as a cause of chronic renal failure is yet to be established.
Epidemiologic and basic research on toxic mechanisms and
interactions must be moved into the clinical arena by properly
designed studies that may, by necessity, require determination
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of body lead burden together with clinicopathologic correla-
tions. Finally, the diagnostic methods of the animal toxicology
laboratory such as urinary enzyme excretion must be tested
clinically. Clinical nephrologists are seemingly irrevocably
wedded to the glomerular filtration rate (as estimated by serum
creatinine or creatinine clearance) as the only valid measure-
ment of significant renal injury. Development of other methods
of assessing renal injury are urgently needed to ascertain
whether low-level exposure to nephrotoxins constitutes an
important cause of chronic renal failure.
Questions and answers
DR. JEROME P. KASSIRER: The evidence supporting a direct
role for lead intoxication as a cause of chronic renal disease
seems to me to be rather circumstantial and not terribly
convincing. The patient you presented today exemplifies this
issue. True, he lived and worked in a contaminated environ-
ment and has an abundance of lead in his body, but these data
hardly constitute evidence that the lead exposure caused his
renal disease. I could argue that the patient has hypertensive
nephrosclerosis or some kind of familial renal disese, and that
the lead overload is coincidental.
DR. BENNETT: Those are precisely the issues that have been
raised in the past, and they are certainly all good points. I argue
that lead nephropathy is as likely a cause as the other alterna-
tives that you might propose in this patient. Most accept as a
fact that primary hypertension can lead to tubulointerstitial
nephropathy of this type, and nephrosclerosis commonly oc-
curs in the absence of lead. This, indeed, is an assumption that
we all make and feel pretty comfortable with, but how many
studies of hypertensives have excluded lead? We simply have
not studied the kinds of patients at high risk. The black, inner-
city individual, for example, who may be exposed to environ-
mental lead, needs to have lead nephropathy actively excluded
before we accept primary hypertensive disease as the cause of
progressive renal failure.
How can we make this giant leap of causality? Some data
show that animals fed lead over months develop chronic
tubulointerstitial disease. In addition, the epidemiologic data
from Australia would have to be explained in some other way.
The two or three decades of remarkable prevalence of contract-
ed kidneys, hypertension, gout in both males and females, and
premature death from renal disease which has recently waned
in the 1970s and '80s fit nicely with the known childhood
exposures.
But you are absolutely right that it is difficult to prove a
cause-and-effect relationship. One question that often comes up
is whether the presence of renal failure per se of any etiology
causes the body burden of lead to go up in individuals with
"normal" exposures. However, when lead excretion in patients
with renal failure from other known causes is examined, lead
excretion is not excessive. Again, you have a problem because
if you accept renal failure patients as control patients, it
presumes you know the etiology of their diseases. If you have
categorized them as having glomerulonephritis on clinical
grounds, which usually translates to proteinuria and occasional-
ly a renal biopsy that is consistent with a chronic glomerular
disorder, you certainly don't have any grounds to exclude lead
nephropathy.
DR. GEORGE A. PORTER (Chairman, Department of Medi-
cine, Oregon Health Sciences University): The epidemiologic
studies that you quoted principally used blood lead as the basis
on which conclusions were drawn. You then showed us a
substantial amount of data in adults that show that blood lead
has little relationship with the renal disease, but instead it is the
body burden of lead that is important. The question is, is there a
difference in the way one interprets the blood lead in children
versus adults? Is the relationship different in children because
of their increased bone turnover? Can we really use blood lead
data from children to interpret the relative risks of lead
nephropathy in adults alter similar exposures?
DR. BENNETT: That is a good question. Children are known
to have sources of exposure to lead that are probably different
than adults. Children, because of different contact with dusts as
well as ingestion of lead, are at increased risk compared to
adults. This is true in view of play habits in areas of high
contamination, like northern Idaho, where soil and air have
high lead contents. Some data suggest that the growing child
does have an increased propensity to deposit lead in bone
because of high bone turnover. However, it is difficult to get a
handle on the precise question that you asked, because almost
all of the epidemiologic studies have measured blood lead.
There are very little data of the kind I quoted where asymptorn-
atic people working in a high lead environment were actually
subjected to chelation studies to estimate their body burdens so
that these values could be correlated with blood lead. Similar
studies are not available in children.
DR. RICHARD PARKER (Nephrologist, Portland): How do you
explain the severity of the biopsy changes in the patient and the
fact that there were only chronic interstitial changes without
acute inflammation and the subsequent improvement in GFR
with chelation therapy? Is this simply another example of poor
correlation of structure and function, or is there a better
explanation?
DR. BENNETT: To be fair, the patients in most studies have
had less severe renal failure prior to chelation. Their biopsies
were not as severely affected as was the sample from the patient
we are discussing today. The GFRs typically have been in the
range of 50 to 70 ml/min. I think the fact that our patient is
stable 3 years later after a course of chelation speaks to the fact
that we may have done something beneficial. I would have
expected with the severity of his blood pressure elevation he
would have progressed to renal failure without treatment of his
underlying disease.
DR. LAWRENCE ELZINOA (Fellow in Nephrology, Oregon
Health Sciences University): What is the mechanism of the
increased uric acid reabsorption, especially in view of the
proximal tubular dysfunction that impairs glucose transport?
DR. BENNETT: I do not know whether anyone knows the
specific mechanism. The most detailed studies have been
clearance studies in humans documenting increased net reab-
sorption. The cellular basis for it hasn't been studied. I don't
know of anything specific relating to lead's effects on uric acid
transport.
DR. KASSIRER: Assuming that there is such a phenomenon as
lead nephropathy, can you explain why some people exposed to
lead never get any renal disease whereas others do?
DR. BENNETT: Again, it depends on how one defines renal
disease. If we define it as BUN and creatinine elevations, I
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think one could argue that our tests are too insensitive to detect
subtle renal disease. I suspect that there is a whole host of
dietary, genetic, and other responses of an individual to any
toxin that determine what the clinical manifestations, if any, are
going to be. lam intrigued by the relationship of lead absorption
with calcium and other trace metals. For example, tin in
increasing concentrations inhibits lead transport in renal slices.
DR. SUSAN KAUFFMAN (Fellow in Nephrology, Oregon
Health Sciences University): Assuming that lead nephropathy
exists and that lead exposure primarily affects proximal tubular
function, is there any role for measurement of urinary 13-2
microglobulin as a marker for renal lead toxicity?
DR. BENNETT: On a theoretical basis, I think that idea is
appealing. However, Hong et al studied 6 people who were
heavily exposed to lead and measured proximal tubular func-
tion in detail. The authors did not find 13-2 microglobulinuria
[10]. On the other hand, Meyer et al looked at proximal tubule
enzyme markers such as N-acetylglucosaminidase and found
them elevated in a group of lead workers [40]. I think all those
enzyme tests unfortunately need to be looked at in the context
of more conventional renal function tests. Correlation with
renal morphology is needed before we can interpret what they
mean. Toxicologists often use sensitive indicators such as
enzymuria as indicators of nephrotoxicity, but what does that
mean in terms of what clinicians deal with? What is the
relationship of enzymuria to GFR and to histopathology? If
there is a correlation, we need to start using these tests
clinically. If enzymuria or 13-2 microglobulinuria are not corre-
lated with subsequent disease in prospective studies, we need
to know that too.
DR. KASSIRER: In your view, what needs to be done to screen
those people exposed to lead for renal disease? If you were
responsible for designing a study of workers in the lead indus-
try, what would you do to identify potential cases of lead
nephropathy?
DR. BENNETT: I think prospective studies with age- and sex-
matched controls are desperately needed. A group of patients
that could be followed over time should be screened at intervals
with sensitive studies like /3-2 microglobulin, urinary enzymes,
and chelation studies. At certain points, correlations have to be
done with conventional tests of glomerular filtration rate and
renal histopathology. This would be a big undertaking, but
because there has been little progress in terms of elucidating
specific causes for most patients with chronic renal failure, I am
convinced that the time has come to undertake such prospec-
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